

INTERNATIONAL SEARCH REPORT

International application No. _____

PCT/US04/39189

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 39/395, 48/00

US CL : 424/144.1; 514/44

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/144.1; 514/44

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
STN, WEST, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MATOU et al. Effect of fucoidan on fibroblast growth factor-2-induced angiogenesis in vitro. Thromb Res. 15 May 2002 (15.05.2002), Vol. 106, No. 4-5, pages 213-221. see abstract, and page 219, 1st col.	1-5, 7-8-9 and 11-13
—		6, 10 and 14
Y		
X	CHABUT et al. Low molecular weight fucoidan and heparin enhance the basic fibroblast growth factor-induced tube formation of endothelial cells through heparan sulfate-dependent alpha6 overexpression. Mol Pharmacol. September 2003, Vol. 64, No. 3, pages 696-702. See abstract and page 698, 2nd col., 1st paragraph.	1-5, 7-8-9 and 11-13
—		6, 10 and 14
Y		
A	HIRAN et al. Endothelial expression of the alpha6beta4 integrin is negatively regulated during angiogenesis. J Cell Sci. 15 September 2003 (15.09.2003), Vo. 116, No. 18, pages 3771-3781.	1-14
A	US 2004/0018192 A1 (WAKABAYASHI et al) (29 January 2004 (29.01.2004).	1-14
Y,P	US 2003/0224993 A1 (LAND et al) 04 December 2003 (04.12.2003), see paragraph 361 on page 38.	6, 10 and 14
Y	KRONENWETT et al. Inhibition of angiogenesis in vitro by alphav integrin-directed antisense oligonucleotides. Cancer Gene Ther. 2002, Vol. 9, No. 7, pages 587-596.	6, 10 and 14

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"B" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

30 March 2005 (30.03.2005)

Date of mailing of the international search report

25 MAY 2005

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

Facsimile No. (703) 305-3230

Authorized officer

Maher M. Haddad

Telephone No. (571) 272-1600